<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">inovmed</journal-id><journal-title-group><journal-title xml:lang="ru">Инновационная медицина Кубани</journal-title><trans-title-group xml:lang="en"><trans-title>Innovative Medicine of Kuban</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2541-9897</issn><publisher><publisher-name>Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.35401/2541-9897-2024-9-3-111-116</article-id><article-id custom-type="elpub" pub-id-type="custom">inovmed-888</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Роль микробиоты кишечника в развитии мочекаменной болезни</article-title><trans-title-group xml:lang="en"><trans-title>Role of the Gut Microbiota in the Development of Urolithiasis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2125-4897</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Павлов</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Pavlov</surname><given-names>V. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Павлов Валентин Николаевич, д. м. н., профессор, академик РАН, заведующий кафедрой урологии и онкологии</p></bio><bio xml:lang="en"><p>Valentin N. Pavlov, Dr. Sci. (Med.), Professor, Academicianof the Russian Academy of Sciences, Head of the Urology and Oncology Department</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-6826-3133</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пушкарев</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Pushkarev</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пушкарев Алексей Михайлович, д. м. н., профессоркафедры урологии и онкологии</p><p>450077, Уфа, ул. Ленина, 3</p></bio><bio xml:lang="en"><p>Aleksey M. Pushkarev, Dr. Sci. (Med.), Professor at theUrology and Oncology Department,</p><p>ulitsa Lenina 3, Ufa, 450077</p></bio><email xlink:type="simple">pushkar967@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4044-0396</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сабирзянов</surname><given-names>С. Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Sabirzyanov</surname><given-names>S. Sh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сабирзянов Сабир Шамильевич, ординатор кафедрыурологии и онкологии</p></bio><bio xml:lang="en"><p>Sabir Sh. Sabirzyanov, Resident, Urology and Oncology Department</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4625-9689</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сергеев</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Sergeev</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сергеев Владимир Витальевич, к. м. н., заведующий отделением урологии № 1</p></bio><bio xml:lang="en"><p>Vladimir V. Sergeev, Cand. Sci. (Med.), Head of the UrologyUnit No. 1</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6442-6161</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чурбаков</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Churbakov</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Чурбаков Василий Вячеславович, врач-уролог, отделение урологии № 1</p></bio><bio xml:lang="en"><p>Vasiliy V. Churbakov, Urologist, Urology Unit No. 1</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-2508-7901</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Газизуллина</surname><given-names>Г. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Gazizullina</surname><given-names>G. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Газизуллина Гульнара Раилевна, заведующая лабораторией микробиома человека</p></bio><bio xml:lang="en"><p>Gulnara R. Gazizullina, Head of the Laboratory of HumanMicrobiome</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3330-9437</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гимранова</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Gimranova</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гимранова Ирина Анатольевна, к. м. н., заведующая кафедрой фундаментальной и прикладной микробиологии</p></bio><bio xml:lang="en"><p>Irina A. Gimranova, Cand. Sci. (Med.), Head of the Department of Fundamental and Applied Microbiology</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0979-0283</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хакимова</surname><given-names>Л. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Khakimova</surname><given-names>L. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Хакимова Лилия Ралисовна, к. б. н, доцент кафедрыфундаментальной и прикладной микробиологии</p></bio><bio xml:lang="en"><p>Liliya R. Khakimova, Cand. Sci. (Bio.), Associate Professor at the Department of Fundamental and Applied Microbiology</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Башкирский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Bashkir State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Краевая клиническая больница № 2</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Regional Clinical Hospital No. 2</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>30</day><month>09</month><year>2024</year></pub-date><volume>0</volume><issue>3</issue><fpage>111</fpage><lpage>116</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Павлов В.Н., Пушкарев А.М., Сабирзянов С.Ш., Сергеев В.В., Чурбаков В.В., Газизуллина Г.Р., Гимранова И.А., Хакимова Л.Р., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Павлов В.Н., Пушкарев А.М., Сабирзянов С.Ш., Сергеев В.В., Чурбаков В.В., Газизуллина Г.Р., Гимранова И.А., Хакимова Л.Р.</copyright-holder><copyright-holder xml:lang="en">Pavlov V.N., Pushkarev A.M., Sabirzyanov S.S., Sergeev V.V., Churbakov V.V., Gazizullina G.R., Gimranova I.A., Khakimova L.R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.innovmedkub.ru/jour/article/view/888">https://www.innovmedkub.ru/jour/article/view/888</self-uri><abstract><p>Основной целью данной работы стал обзор мировой литературы по вопросам оценки влияния микробиоты кишечника на образование камней в почках. Авторами была поставлена задача определить, указано ли в данных публикациях на несколько конкретных кишечных бактерий или за эту взаимосвязь несет ответственность более широкое число представителей микробиоты кишечника. Проведен обширный поиск литературы в PubMed, Cochrane central и Web of Science Core CollectionScience на предмет роли микробиоты кишечника в образовании камней в почках (2013–2023 гг.). Большое количество более ранних исследований камней в почках было сосредоточено на физико-химических свойствах кристаллов, образуемых камнями. Но в последние годы с улучшением диагностических технологий прослеживается тенденция к изучению связи микробиоты кишечника с развитием других, не связанных заболеваний. Появились работы, где показано влияние микробиоты кишечника на развитие мочекаменной болезни, что дает основание полагать, что образование камней можно предотвратить или вызвать путем изменения структуры микробиома кишечника. Однако необходимы дальнейшие исследования по изучению вопросов родов или видов кишечной микробиоты, влияющих на расщепление оксалатов, а также снижение риска образования камней в почках. </p></abstract><trans-abstract xml:lang="en"><p>This article aims to review the literature regarding assessment of the gut microbiota effect on kidney stone formation. We sought to determine whether several specific gut bacteria or a wider number of members of the gut microbiota are responsible for this association based on the literature data. We conducted an extensive literature search (publications on kidney stones and gut microbiota dated 2013-2023) in PubMed, Cochrane CENTRAL, and Web of Science Core Collection.</p><p>A large number of earlier studies were focused on physical and chemical properties of crystals formed by kidney stones. In recent years as diagnostic technologies advance, there has been a tendency to study the association of the gut microbiota and the development of other unrelated diseases. Studies have emerged showing the gut microbiota effect on the development of urolithiasis, which suggests that stone formation can be prevented or caused by changing the structure of the gut microbiome. However, further research is needed to identify which genera or types of the gut microbiota break down oxalate and reduce the risk of kidney stone formation. </p></trans-abstract><kwd-group xml:lang="ru"><kwd>микробиота кишечника</kwd><kwd>мочекаменная болезнь</kwd><kwd>камни в почках</kwd><kwd>технология секвенирования</kwd></kwd-group><kwd-group xml:lang="en"><kwd>gut microbiota</kwd><kwd>urolithiasis</kwd><kwd>kidney stones</kwd><kwd>sequencing technology</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Российское общество урологов. Клинические рекомендации «Мочекаменная болезнь». Российское общество урологов; 2020.</mixed-citation><mixed-citation xml:lang="en">Russian Society of Urology. Clinical Guidelines. Urolithiasis. Russian Society of Urologists; 2020. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Sorokin I, Mamoulakis C, Miyazawa K, Rodgers A, Talati J, Lotan Y. Epidemiology of stone disease across the world. World J Urol. 2017;35(9):1301–1320. PMID: 28213860. https://doi.org/10.1007/s00345-017-2008-6</mixed-citation><mixed-citation xml:lang="en">Sorokin I, Mamoulakis C, Miyazawa K, Rodgers A, Talati J, Lotan Y. Epidemiology of stone disease across the world. World J Urol. 2017;35(9):1301–1320. PMID: 28213860. https://doi.org/10.1007/s00345-017-2008-6</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Moe OW. Kidney stones: pathophysiology and medical management. Lancet. 2006;367(9507):333–344. PMID: 16443041. https://doi.org/10.1016/S0140-6736(06)68071-9</mixed-citation><mixed-citation xml:lang="en">Moe OW. Kidney stones: pathophysiology and medical management. Lancet. 2006;367(9507):333–344. PMID: 16443041. https://doi.org/10.1016/S0140-6736(06)68071-9</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Buttó LF, Haller D. Dysbiosis in Crohn’s disease - joint action of stochastic injuries and focal inflammation in the gut. Gut Microbes. 2017;8(1):53–58. PMID: 28102757. PMCID: PMC5341912. https://doi.org/10.1080/19490976.2016.1270810</mixed-citation><mixed-citation xml:lang="en">Buttó LF, Haller D. Dysbiosis in Crohn’s disease - joint action of stochastic injuries and focal inflammation in the gut. Gut Microbes. 2017;8(1):53–58. PMID: 28102757. PMCID: PMC5341912. https://doi.org/10.1080/19490976.2016.1270810</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Miller AW, Choy D, Penniston KL, Lange D. Inhibition of urinary stone disease by a multi-species bacterial network ensures healthy oxalate homeostasis. Kidney Int. 2019;96(1):180– 188. PMID: 31130222. PMCID: PMC6826259. https://doi.org/10.1016/j.kint.2019.02.012</mixed-citation><mixed-citation xml:lang="en">Miller AW, Choy D, Penniston KL, Lange D. Inhibition of urinary stone disease by a multi-species bacterial network ensures healthy oxalate homeostasis. Kidney Int. 2019;96(1):180– 188. PMID: 31130222. PMCID: PMC6826259. https://doi.org/10.1016/j.kint.2019.02.012</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Singh P, Enders FT, Vaughan LE, et al. Stone composition among first-time symptomatic kidney stone formers in the community. Mayo Clin Proc. 2015;90(10):1356–1365. PMID: 26349951. PMCID: PMC4593754. https://doi.org/10.1016/j.mayocp.2015.07.016</mixed-citation><mixed-citation xml:lang="en">Singh P, Enders FT, Vaughan LE, et al. Stone composition among first-time symptomatic kidney stone formers in the community. Mayo Clin Proc. 2015;90(10):1356–1365. PMID: 26349951. PMCID: PMC4593754. https://doi.org/10.1016/j. mayocp.2015.07.016</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Dhondup T, Kittanamongkolchai W, Vaughan LE, et al. Risk of ESRD and mortality in kidney and bladder stone formers. Am J Kidney Dis. 2018;72(6):790–797. PMID: 30146423. PMCID: PMC6252145. https://doi.org/10.1053/j.ajkd.2018.06.012</mixed-citation><mixed-citation xml:lang="en">Dhondup T, Kittanamongkolchai W, Vaughan LE, et al. Risk of ESRD and mortality in kidney and bladder stone formers. Am J Kidney Dis. 2018;72(6):790–797. PMID: 30146423. PMCID: PMC6252145. https://doi.org/10.1053/j.ajkd.2018.06.012</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Shoag J, Halpern J, Goldfarb DS, Eisner BH. Risk of chronic and end stage kidney disease in patients with nephrolithiasis. J Urol. 2014;192(5):1440–1445. PMID: 24929140. https://doi.org/10.1016/j.juro.2014.05.117</mixed-citation><mixed-citation xml:lang="en">Shoag J, Halpern J, Goldfarb DS, Eisner BH. Risk of chronic and end stage kidney disease in patients with nephrolithiasis. J Urol. 2014;192(5):1440–1445. PMID: 24929140. https://doi.org/10.1016/j.juro.2014.05.117</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Brzica H, Breljak D, Burckhardt BC, Burckhardt G, Sabolić I. Oxalate: from the environment to kidney stones. Arh Hig Rada Toksikol. 2013;64(4):609–630. PMID: 24384768. https://doi.org/10.2478/10004-1254-64-2013-2428</mixed-citation><mixed-citation xml:lang="en">Brzica H, Breljak D, Burckhardt BC, Burckhardt G, Sabolić I. Oxalate: from the environment to kidney stones. Arh Hig Rada Toksikol. 2013;64(4):609–630. PMID: 24384768. https://doi. org/10.2478/10004-1254-64-2013-2428</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ferraro PM, Bargagli M, Trinchieri A, Gambaro G. Risk of kidney stones: influence of dietary factors, dietary patterns, and vegetarian-vegan diets. Nutrients. 2020;12(3):779. PMID: 32183500. PMCID: PMC7146511. https://doi.org/10.3390/nu12030779</mixed-citation><mixed-citation xml:lang="en">Ferraro PM, Bargagli M, Trinchieri A, Gambaro G. Risk of kidney stones: influence of dietary factors, dietary patterns, and vegetarian-vegan diets. Nutrients. 2020;12(3):779. PMID: 32183500. PMCID: PMC7146511. https://doi.org/10.3390/nu12030779</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Howles SA, Thakker RV. Genetics of kidney stone disease. Nat Rev Urol. 2020;17(7):407–421. PMID: 32533118. https://doi.org/10.1038/s41585-020-0332-x</mixed-citation><mixed-citation xml:lang="en">Howles SA, Thakker RV. Genetics of kidney stone disease. Nat Rev Urol. 2020;17(7):407–421. PMID: 32533118. https://doi.org/10.1038/s41585-020-0332-x</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Khan SR, Pearle MS, Robertson WG, et al. Kidney stones. Nat Rev Dis Primers. 2016;2:16008. PMID: 27188687. PMCID: PMC5685519. https://doi.org/10.1038/nrdp.2016.8</mixed-citation><mixed-citation xml:lang="en">Khan SR, Pearle MS, Robertson WG, et al. Kidney stones. Nat Rev Dis Primers. 2016;2:16008. PMID: 27188687. PMCID: PMC5685519. https://doi.org/10.1038/nrdp.2016.8</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Xiang L, Jin X, Liu Y, et al. Prediction of the occurrence of calcium oxalate kidney stones based on clinical and gut microbiota characteristics. World J Urol. 2022;40(1):221–227. PMID: 34427737. PMCID: PMC8813786. https://doi.org/10.1007/s00345-021-03801-7</mixed-citation><mixed-citation xml:lang="en">Xiang L, Jin X, Liu Y, et al. Prediction of the occurrence of calcium oxalate kidney stones based on clinical and gut microbiota characteristics. World J Urol. 2022;40(1):221–227. PMID: 34427737. PMCID: PMC8813786. https://doi.org/10.1007/s00345-021-03801-7</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Yuan T, Xia Y, Li B, et al. Gut microbiota in patients with kidney stones: a systematic review and meta-analysis. BMC Microbiol. 2023;23(1):143. PMID: 37208622. PMCID: PMC10197343. https://doi.org/10.1186/s12866-023-02891-0</mixed-citation><mixed-citation xml:lang="en">Yuan T, Xia Y, Li B, et al. Gut microbiota in patients with kidney stones: a systematic review and meta-analysis. BMC Microbiol. 2023;23(1):143. PMID: 37208622. PMCID: PMC10197343. https://doi.org/10.1186/s12866-023-02891-0</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Siva S, Barrack ER, Reddy GP, et al. A critical analysis of the role of gut Oxalobacter formigenes in oxalate stone disease. BJU Int. 2009;103(1):18–21. PMID: 19021605. https://doi.org/10.1111/j.1464-410X.2008.08122.x</mixed-citation><mixed-citation xml:lang="en">Siva S, Barrack ER, Reddy GP, et al. A critical analysis of the role of gut Oxalobacter formigenes in oxalate stone disease. BJU Int. 2009;103(1):18–21. PMID: 19021605. https://doi.org/10.1111/j.1464-410X.2008.08122.x</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Siener R, Bangen U, Sidhu H, Hönow R, von Unruh G, Hesse A. The role of Oxalobacter formigenes colonization in calcium oxalate stone disease. Kidney Int. 2013;83(6):1144–1149. PMID: 23536130. https://doi.org/10.1038/ki.2013.104</mixed-citation><mixed-citation xml:lang="en">Siener R, Bangen U, Sidhu H, Hönow R, von Unruh G, Hesse A. The role of Oxalobacter formigenes colonization in calcium oxalate stone disease. Kidney Int. 2013;83(6):1144–1149. PMID: 23536130. https://doi.org/10.1038/ki.2013.104</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Tang R, Jiang Y, Tan A, et al. 16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones. Urolithiasis. 2018;46(6):503–514. PMID: 29353409. https://doi.org/10.1007/s00240-018-1037-y</mixed-citation><mixed-citation xml:lang="en">Tang R, Jiang Y, Tan A, et al. 16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones. Urolithiasis. 2018;46(6):503–514. PMID: 29353409. https://doi.org/10.1007/s00240-018-1037-y</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Stern JM, Moazami S, Qiu Y, et al. Evidence for a distinct gut microbiome in kidney stone formers compared to non-stone formers. Urolithiasis. 2016;44(5):399–407. PMID: 27115405. PMCID: PMC8887828. https://doi.org/10.1007/s00240-016-0882-9</mixed-citation><mixed-citation xml:lang="en">Stern JM, Moazami S, Qiu Y, et al. Evidence for a distinct gut microbiome in kidney stone formers compared to non-stone formers. Urolithiasis. 2016;44(5):399–407. PMID: 27115405. PMCID: PMC8887828. https://doi.org/10.1007/s00240-016-0882-9</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kim HN, Kim JH, Chang Y, et al. Gut microbiota and the prevalence and incidence of renal stones. Sci Rep. 2022;12(1):3732. PMID: 35260689. PMCID: PMC8904816. https://doi.org/10.1038/s41598-022-07796-y</mixed-citation><mixed-citation xml:lang="en">Kim HN, Kim JH, Chang Y, et al. Gut microbiota and the prevalence and incidence of renal stones. Sci Rep. 2022;12(1):3732. PMID: 35260689. PMCID: PMC8904816. https://doi.org/10.1038/ s41598-022-07796-y</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Cao C, Fan B, Zhu J, Zhu N, Cao JY, Yang DR. Association of gut microbiota and biochemical features in a Chinese population with renal uric acid stone. Front Pharmacol. 2022;13:888883. PMID: 35662733. PMCID: PMC9160931. https://doi.org/10.3389/fphar.2022.888883</mixed-citation><mixed-citation xml:lang="en">Cao C, Fan B, Zhu J, Zhu N, Cao JY, Yang DR. Association of gut microbiota and biochemical features in a Chinese population with renal uric acid stone. Front Pharmacol. 2022;13:888883. PMID: 35662733. PMCID: PMC9160931. https://doi.org/10.3389/fphar.2022.888883</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ticinesi A, Milani C, Guerra A, et al. Understanding the gut-kidney axis in nephrolithiasis: an analysis of the gut microbiota composition and functionality of stone formers. Gut. 2018;67(12):2097–2106. PMID: 29705728. https://doi.org/10.1136/gutjnl-2017-315734</mixed-citation><mixed-citation xml:lang="en">Ticinesi A, Milani C, Guerra A, et al. Understanding the gut-kidney axis in nephrolithiasis: an analysis of the gut microbiota composition and functionality of stone formers. Gut. 2018;67(12):2097–2106. PMID: 29705728. https://doi.org/10.1136/gutjnl-2017-315734</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Tavasoli S, Alebouyeh M, Naji M, et al. Association of intestinal oxalate-degrading bacteria with recurrent calcium kidney stone formation and hyperoxaluria: a case-control study. BJU Int. 2020;125(1):133–143. PMID: 31145528. https://doi.org/10.1111/bju.14840</mixed-citation><mixed-citation xml:lang="en">Tavasoli S, Alebouyeh M, Naji M, et al. Association of intestinal oxalate-degrading bacteria with recurrent calcium kidney stone formation and hyperoxaluria: a case-control study. BJU Int. 2020;125(1):133–143. PMID: 31145528. https://doi.org/10.1111/bju.14840</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Lieske JC. Probiotics for prevention of urinary stones. Ann Transl Med. 2017;5(2):29. PMID: 28217694. PMCID: PMC5300857. https://doi.org/10.21037/atm.2016.11.86</mixed-citation><mixed-citation xml:lang="en">Lieske JC. Probiotics for prevention of urinary stones. Ann Transl Med. 2017;5(2):29. PMID: 28217694. PMCID: PMC5300857. https://doi.org/10.21037/atm.2016.11.86</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Denburg MR, Koepsell K, Lee JJ, Gerber J, Bittinger K, Tasian GE. Perturbations of the gut microbiome and metabolome in children with calcium oxalate kidney stone disease. J Am Soc Nephrol. 2020;31(6):1358–1369. PMID: 32381601. PMCID: PMC7269359. https://doi.org/10.1681/ASN.2019101131</mixed-citation><mixed-citation xml:lang="en">Denburg MR, Koepsell K, Lee JJ, Gerber J, Bittinger K, Tasian GE. Perturbations of the gut microbiome and metabolome in children with calcium oxalate kidney stone disease. J Am Soc Nephrol. 2020;31(6):1358–1369. PMID: 32381601. PMCID: PMC7269359. https://doi.org/10.1681/ASN.2019101131</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Suryavanshi MV, Bhute SS, Jadhav SD, Bhatia MS, Gune RP, Shouche YS. Hyperoxaluria leads to dysbiosis and drives selective enrichment of oxalate metabolizing bacterial species in recurrent kidney stone endures. Sci Rep. 2016;6:34712. PMID: 27708409. PMCID: PMC5052600. https://doi.org/10.1038/srep34712</mixed-citation><mixed-citation xml:lang="en">Suryavanshi MV, Bhute SS, Jadhav SD, Bhatia MS, Gune RP, Shouche YS. Hyperoxaluria leads to dysbiosis and drives selective enrichment of oxalate metabolizing bacterial species in recurrent kidney stone endures. Sci Rep. 2016;6:34712. PMID: 27708409. PMCID: PMC5052600. https://doi.org/10.1038/srep34712</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Stanford J, Charlton K, Stefoska-Needham A, Ibrahim R, Lambert K. The gut microbiota profile of adults with kidney disease and kidney stones: a systematic review of the literature. BMC Nephrol. 2020;21(1):215. PMID: 32503496. PMCID: PMC7275316. https://doi.org/10.1186/s12882-020-01805-w</mixed-citation><mixed-citation xml:lang="en">Stanford J, Charlton K, Stefoska-Needham A, Ibrahim R, Lambert K. The gut microbiota profile of adults with kidney disease and kidney stones: a systematic review of the literature. BMC Nephrol. 2020;21(1):215. PMID: 32503496. PMCID: PMC7275316. https://doi.org/10.1186/s12882-020-01805-w</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Chen F, Bao X, Liu S, et al. Gut microbiota affect the formation of calcium oxalate renal calculi caused by high daily tea consumption. Appl Microbiol Biotechnol. 2021;105(2):789–802. PMID: 33404827. https://doi.org/10.1007/s00253-020-11086-w</mixed-citation><mixed-citation xml:lang="en">Chen F, Bao X, Liu S, et al. Gut microbiota affect the formation of calcium oxalate renal calculi caused by high daily tea consumption. Appl Microbiol Biotechnol. 2021;105(2):789–802. PMID: 33404827. https://doi.org/10.1007/s00253-020-11086-w</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Cabrera C, Artacho R, Giménez R. Beneficial effects of green tea--a review. J Am Coll Nutr. 2006;25(2):79–99. PMID: 16582024. https://doi.org/10.1080/07315724.2006.10719518</mixed-citation><mixed-citation xml:lang="en">Cabrera C, Artacho R, Giménez R. Beneficial effects of green tea--a review. J Am Coll Nutr. 2006;25(2):79–99. PMID: 16582024. https://doi.org/10.1080/07315724.2006.10719518</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Yang Y, Zhang X, Weng PF, Wu ZF. In vitro monitoring of the probiotic activity of tea catechins on human intestinal flora. Modern Food Science and Technology. 2015;31(4):128–136.</mixed-citation><mixed-citation xml:lang="en">Yang Y, Zhang X, Weng PF, Wu ZF. In vitro monitoring of the probiotic activity of tea catechins on human intestinal flora. Modern Food Science and Technology. 2015;31(4):128–136.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Tasian GE, Jemielita T, Goldfarb DS, et al. Oral antibiotic exposure and kidney stone disease. J Am Soc Nephrol. 2018;29(6):1731–1740. PMID: 29748329. PMCID: PMC6054354. https://doi.org/10.1681/ASN.2017111213</mixed-citation><mixed-citation xml:lang="en">Tasian GE, Jemielita T, Goldfarb DS, et al. Oral antibiotic exposure and kidney stone disease. J Am Soc Nephrol. 2018;29(6):1731–1740. PMID: 29748329. PMCID: PMC6054354. https://doi.org/10.1681/ASN.2017111213</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Y, Sun J, Xie S, et al. Increased abundance of bacteria of the family Muribaculaceae achieved by fecal microbiome transplantation correlates with the inhibition of kidney calcium oxalate stone deposition in experimental rats. Front Cell Infect Microbiol. 2023;13:1145196. PMID: 37313343. PMCID: PMC10258309. https://doi.org/10.3389/fcimb.2023.1145196</mixed-citation><mixed-citation xml:lang="en">Wang Y, Sun J, Xie S, et al. Increased abundance of bacteria of the family Muribaculaceae achieved by fecal microbiome transplantation correlates with the inhibition of kidney calcium oxalate stone deposition in experimental rats. Front Cell Infect Microbiol. 2023;13:1145196. PMID: 37313343. PMCID: PMC10258309. https://doi.org/10.3389/fcimb.2023.1145196</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Mehra Y, Rajesh NG, Viswanathan P. Analysis and characterization of Lactobacillus paragasseri and Lacticaseibacillus paracasei: two probiotic bacteria that can degrade intestinal oxalate in hyperoxaluric rats. Probiotics Antimicrob Proteins. 2022;14(5):854–872. PMID: 35699895. https://doi.org/10.1007/s12602-022-09958-w</mixed-citation><mixed-citation xml:lang="en">Mehra Y, Rajesh NG, Viswanathan P. Analysis and characterization of Lactobacillus paragasseri and Lacticaseibacillus paracasei: two probiotic bacteria that can degrade intestinal oxalate in hyperoxaluric rats. Probiotics Antimicrob Proteins. 2022;14(5):854–872. PMID: 35699895. https://doi.org/10.1007/s12602-022-09958-w</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Tian L, Liu Y, Xu X, et al. Lactiplantibacillus plantarum J-15 reduced calcium oxalate kidney stones by regulating intestinal microbiota, metabolism, and inflammation in rats. FASEB J. 2022;36(6):e22340. PMID: 35524736. https://doi.org/10.1096/fj.202101972RR</mixed-citation><mixed-citation xml:lang="en">Tian L, Liu Y, Xu X, et al. Lactiplantibacillus plantarum J-15 reduced calcium oxalate kidney stones by regulating intestinal microbiota, metabolism, and inflammation in rats. FASEB J. 2022;36(6):e22340. PMID: 35524736. https://doi.org/10.1096/ fj.202101972RR</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Wu F, Cheng Y, Zhou J, et al. Zn2+ regulates human oxalate mtabolism by manipulating oxalate decarboxylase to treat calcium oxalate stones. Int J Biol Macromol. 2023;234:123320. PMID: 36682657. https://doi.org/10.1016/j.ijbiomac.2023.123320</mixed-citation><mixed-citation xml:lang="en">Wu F, Cheng Y, Zhou J, et al. Zn2+ regulates human oxalate metabolism by manipulating oxalate decarboxylase to treat calcium oxalate stones. Int J Biol Macromol. 2023;234:123320. PMID: 36682657. https://doi.org/10.1016/j.ijbiomac.2023.123320</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
